title: Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.
abstract: BACKGROUND
  No standard second-line combination chemotherapy has yet been established for patients with recurrent small cell lung cancer (RSCLC).
  
  
  METHODS
  Patients with RSCLC were treated with nedaplatin (NP) at 50 mg/m2 and irinotecan (CPT) at 50 mg/m2 on days 1 and 8 every 4 weeks for four cycles.
  
  
  RESULTS
  The clinical outcomes of 12 patients (9 male and 3 female; age range 48-76 years, median 62 years) were retrospectively analyzed. Seven of the patients showed sensitive relapse. Two patients had a performance status of 2. Nine of the patients were able to receive 4 to 6 courses of NP and CPT chemotherapy. Grade 3 or 4 anemia, neutropenia and thrombocytopenia occurred in 25.0%, 50.0% and 41.7% of patients, respectively. There were no grade 3 or 4 non-hematologic toxicities except for febrile neutropenia in 1 patient. There was no treatment-related death. Nine patients achieved PR, and the objective response rate was 75.0%. The median survival time was 11.1 months (range 4.8 to 31.3+ months) and the 1-year survival rate was 50.0%.
  
  
  CONCLUSIONS
  NP and CPT in combination are effective and safe for patients with RSCLC.
authors.affiliation: Department of Thoracic Oncology, Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan.
authors.forename: Miki
authors.initials: M
authors.lastname: Ohe
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Oshita
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kenmotsu
authors.forename: Makiko
authors.initials: M
authors.lastname: Sugiura
authors.forename: Shuji
authors.initials: S
authors.lastname: Murakami
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kondo
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Saito
authors.forename: Kouzo
authors.initials: K
authors.lastname: Yamada
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000473:pathology; D015996:Survival Rate
chemical_list: D009944:Organoplatinum Compounds; D000077146:Irinotecan; C053989:nedaplatin; D002166:Camptothecin